Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Payables (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Payables for 7 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 9.99% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, down 9.99%, and an annual FY2025 reading of $3.9 million, down 9.99% over the prior year.
  • Payables was $3.9 million for Q4 2025 at aTYR PHARMA, down from $4.1 million in the prior quarter.
  • Across five years, Payables topped out at $4.9 million in Q1 2024 and bottomed at $516000.0 in Q2 2023.
  • Average Payables over 5 years is $2.6 million, with a median of $2.7 million recorded in 2021.
  • The sharpest move saw Payables skyrocketed 268.82% in 2021, then tumbled 69.18% in 2023.
  • Year by year, Payables stood at $1.0 million in 2021, then soared by 201.26% to $3.1 million in 2022, then grew by 13.62% to $3.5 million in 2023, then increased by 22.5% to $4.3 million in 2024, then dropped by 9.99% to $3.9 million in 2025.
  • Business Quant data shows Payables for ATYR at $3.9 million in Q4 2025, $4.1 million in Q3 2025, and $3.9 million in Q2 2025.